An expert pharmacovigilance and clinical safety leader with more than 20 years of experience in his field, Vasudev Bhupathi works to ensure the safety and efficacy of pharmaceutical products. Bhupathi manages global drug safety strategies related to oncology, immuno-oncology, infectious diseases, and more, helping to build safer therapeutics and biologics through his contributions.
Academic Foundations
Bhupathi’s career is supported by a robust education. He completed a bachelor’s degree in pharmacy at Osmania University, India, in 2004. In 2006, he earned a Master of Business Administration in organizational leadership at the International College of Scotland – Halifax University.
Later, Bhupathi completed an additional master’s degree in computer and information systems security and information assurance at Wilmington University in 2015. He is currently pursuing a Doctor of Public Health in epidemiology from Walden University.
A Well-Rounded Career
Following his graduation from Osmania University, Bhupathi moved between several roles in the pharmaceutical industry. He has held positions as a clinical research associate, senior quality assurance analyst, pharmacovigilance officer, senior principal scientist, global director for pharmacovigilance, and more. He made some of his most notable contributions at Bristol-Myers Squibb, Alkermes, and Moderna Inc.
Bhupathi’s Career Highlights
From 2014 to 2017, Bhupathi worked at Bristol-Myers Squibb, where he was instrumental in advancing safety monitoring infrastructure for immuno-oncology therapies. Notably, he implemented a comprehensive aggregate safety data review, enabling early signal detection to optimize clinical development strategies.
As a senior pharmacovigilance scientist at Alkermes from 2017 to 2020, Bhupathi developed and led a pooling and surveillance strategy for neurological drug candidates. His development pharmacovigilance plan contributed directly to the company’s successful new drug application submission to the Food and Drug Administration and subsequent market approval.
While operating as associate director of pharmacovigilance at Moderna Inc. in Massachusetts, Bhupathi was tasked with overseeing real-time pharmacovigilance operations for the mRNA COVID-19 vaccine program. In this challenging environment, he implemented rigorous safety monitoring to proactively track safety concerns and ensure the success of Moderna’s vaccine safety communications.
Leading as Director of Pharmacovigilance
For his contributions at Moderna Inc. during the COVID-19 pandemic, Bhupathi was appointed as director of pharmacovigilance in 2022, a role he still occupies today. Currently, he is leading the implementation of the aggregate safety analysis plan, a framework designed to evaluate safety systems across multiple clinical development programs. Additionally, Bhupathi facilitated multiple breakthrough approvals and reinforced best practices in signal detection, aggregate reporting, and compliance. His leadership in these roles cemented a culture of data-driven decision-making, ensuring patient welfare remained the foremost priority in drug development. In doing so, he is enhancing the company’s pharmacovigilance rigor in order to adapt to a rapidly changing medical landscape.
Civic Involvement and Memberships
Outside of his professional contributions, Bhupathi is an active contributor to the scientific community. He is currently a member of the Scientific Advisory Committee (SAC) Regulatory Response Subcommittee with the American Association of Pharmaceutical Scientists (AAPS) and serves on the Editorial Advisory Board of PharmaFocus America. He holds multiple associations, such as the Drug Information Association-North America (DIA), the Infectious Diseases Society of America (IDSA), the American Association of Pharmaceutical Scientists (AAPS), and the International Society of Pharmacovigilance (ISOP).
Plans for the Future
Moving forward, Bhupathi hopes to integrate automation into some of pharmacovigilance’s most significant processes through a standardized system and the utilization of artificial intelligence. This way, companies can ensure more efficient and reliable safety practices and hold higher standards in the future. Additionally, Bhupathi is actively studying the safety of drugs and biologics in various therapeutic areas.
